Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
Related Content
-
Daniel E. Bauer, MD, PhDDaniel E. Bauer is currently engaged as ...
-
Webinar Series: Sickle Cell Science: Path to Progress – Sickle Cell Disease Care in the Emergency Department: ...To commemorate Sickle Cell Awareness Mon...
-
Maria Grazia Roncarolo, MDMaria Grazia Roncarolo, MD is the co-dir...
-
Teens with Sickle Cell Disease Moving from Pediatric Care to Adult CareMoving from pediatric (children’s) car...
-
2019 Chicago Sickle Cell SummitThe Chicago Sickle Cell Summit convenes ...
-
Quality of care in sickle cell disease: Cross-sectional study and development of a measure for adults reporting on a...Documented deficiencies in adult sickle ...
-
The 2020 ASPHO Conference – CANCELEDMore than 1,200 pediatric hematology/onc...